Table 3.
Tofacitinib as induction therapy in Crohn’s disease
Phase/study | Treatment | Size | Clinical response | Clinical remission |
---|---|---|---|---|
Phase II Sandborn et al 2014 | Placebo 1 mg BID 5 mg BID 15 mg BID |
34 36 34 35 |
47% 36% (p=0.467) 58% (p=0.466) 46% (p≥0.999) |
21% 31% (p=0.417) 24% (p=0.776) 14% (p=0.540) |
Phase IIb Induction Panés et al 2017 | Placebo 5 mg BID 10 mg BID |
91 86 86 |
62% 76.5% (p<0.05) 74.4% (p>0.05) |
36.7% 43% (0.325) 43% (0.392) |
Abbreviation: BID, twice daily.